Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.60 |
| ▸ | RAB9A | P51151 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | AHR | P35869 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | LCK | P06239 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12162761 | 0.87 | NPC1 (0.48) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL12460960 | 0.83 | NPC1 (0.84) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL16757197 | 0.80 | RAB9A (0.44) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL48387 | 0.79 | ALDH1A1 (0.53) | NPC1RAB9AALDH1A1LCK | |
| SCHEMBL3590753 | 0.79 | LMNA (0.64) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL2753548 | 0.78 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL3138145 | 0.78 | RAB9A (0.57) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL31461127 | 0.76 | LCK (0.50) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL10719011 | 0.73 | NPC1 (0.60) | NPC1RAB9ASMN1; SMN2MEN1KMT2A | |
| SCHEMBL27758932 | 0.73 | ALDH1A1 (0.60) | MEN1KMT2ALMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268818-B2 | Inhibitors of C-MET and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268818-B2 | Inhibitors of C-MET and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268818-B2 | Inhibitors of C-MET and uses thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20100144721-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144721-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| US-20100144721-A1 | INHIBITORS OF C-MET AND USES THEREOF | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-06-10 | — | — | US | disclosed |
| EP-2061787-A2 | 5-(2-FURYL)-1,3-THIAZOLE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | Vertex Pharmaceuticals Incorporated (US) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008027584-A2 | 5- (2-FURYL)-1, 3-THIAZOLE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
| WO-2008027584-A2 | 5- (2-FURYL)-1, 3-THIAZOLE DERIVATIVES USEFUL AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144721-A1 | INHIBITORS OF C-MET AND USES THEREOF | MET, PIK3CA, AKT1 | NPC1 1260/4885RAB9A 1068/4885SMN1; SMN2 2480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.